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1. Introduction 
The members of the Herpesvirales containing more than 130 different herpesviruses have 
already been isolated from all animal species representing the higher steps of evolution. 
According to our knowledge, eight herpesviruses are classified as human herpesviruses: 
Herpes simplex virus 1 (Human herpesvirus 1, HHV-1), Herpes simplex virus 2 (Human 
herpesvirus 2, HHV-2), Varicella-zoster virus (Human herpesvirus 3, HHV-3), Epstein-Barr 
virus (Human herpesvirus 4, HHV-4), Cytomegalovirus (Human herpesvirus 5, HHV-5), 
Human herpesvirus 6 (HHV-6A and HHV-6B), Human herpesvirus 7 (HHV-7), and Human 
herpesvirus 8 (HHV-8 or Kaposi's sarcoma associated herpesvirus, KSHV).  
It is a characteritic of herpesviral infections that after the frequently fulminant initial 
infection, they persist in the neurons or the B- and T-cells of the body throughout life. 
Sometimes they reactivate. With respect to lymphotropic human herpesviruses, HHV-4 and 
HHV-8 reproduce mainly in the B-cells, while HHV-5, HHV-6 and HHV-7 reproduce in T-
cells. HHV-4 causes most of the infectious mononucleosis cases and can immortalize B-
lymphocytes. HHV-5 can also cause infectious mononucleosis. A significant part of primary 
infections occurs in an asymptomatic way. Immunsuppression makes virus reproduction 
easier.  
A wide range of diseases may appear in an immunodeficient state. HHV-6 was first 
described in 1986 and was isolated from patients suffering from lymphoproliferative 
disease. It infects CD4+ T-lymphocytes and it reproduces in them. Two variants of it, HHV-
6A and HHV-6B, are known. Variant B is the pathogen of exanthema subitum (roseola 
infantum) and it can also cause latent infection with fever, diarrhoea, neural symptoms, and 
hepatitis. After transplantation, HHV-6 can reactivate and it is able to replicate in liver-cells. 
HHV-6 can activate the replication of HHV-4; it reduces or increases the replication of HIV, 
and accelerates the expression of antigens coded by HPV. HHV-7 was isolated from CD4+ 
cells in 1990 and was purified from a healthy patient. It is the pathogen of pityriasis rosea, 
but it can also cause exanthema subitum. Additionally, it can create latent infection in T-
lymphocytes and productive infection in salivary gland epithelial cells. During pregnancy, 
viremia is more frequent and may adopt urogenital, perigenital and congenital 
transmission.  
HHV-7 may play a role in cases of immunodeficient patients; in the case of 
immunosuppression HHV-6 and HHV-7 play the role of cofactor in states accompanied by 
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pneumonia. HHV-8 is the latest identified human tumorvirus; since its discovery in 1994 it 
has been in the limelight of research. It plays a critical role in the AIDS-associated body 
cavity B-cell lymphoma (BCBL). The new virus was named Kaposi's sarcoma associated 
herpesvirus (KSHV). Four clinical forms of Kaposi's sarcoma are known: 1. classical type 
(described by Kaposi), 2. epidemic-African type, 3. iatrogen, and 4. AIDS associated type. It 
is possible that KSHV plays a direct or indirect stimulating role: in BCBL in elderly patients 
or ones suffering from AIDS, and in Castleman disease. 
Viral infections are important causes of morbidity and mortality for patients with 
haematological diseases and haematological malignancies. However, the true incidence 
and consequences of human herpesviral infections for these patients who undergo 
conventional nontransplantant therapy are poorly defined. The difference in incidence 
and outcome of viral infections among patient groups is wide, but dependent upon the 
infections among the intensity and duration of T-cell-mediated immune suppression. 
Infections are caused mainly by cytomegalovirus (CMV), herpes simplex virus (HSV), 
varicella-zoster virus (VZV) and less Epstein-Barr virus (EBV), human herpesvirus 6, 7, 8 
(HHV-6, HHV-7, HHV-8). 
Fortunately, a growing number of antiviral medications and vaccines are allowing for more 
effective prophylaxis against these pathogens. 
Modern virology diagnostics use multiple methods for detecting viral infections. These 
include viral isolation in culture, cytologic staining, detection of viral antigens, nucleic acids, 
and viral antibodies. 
Science has been examining the role of herpesviruses in haematologic malignant cases and 
in plasma-cell dyscrasias for decades now. Plasma-cell diseases (monoclonal gammopathies) 
are multiple myeloma (MM), Waldenstörm macroglobulinaemia (WM), and monoclonal 
gammopathy with unknown significance (MGUS). A potential role of HHV-8 has emerged 
in the pathogenesis of these diseases.  
The increase in the number of histiocytes is characteristic of eosinophil granuloma 
(Langerhans cell histiocytosis, LCH). The causal role of lymphotropic herpesviruses has also 
been suggested in the pathogenesis of LCH. The rate of HHV-8 reactivation in patients 
suffering from monoclonal gammopathies significantly exceeds that of those suffering from 
Non-Hodgkins lymphoma. HHV-8 reactivation may refer to immunological lesion in 
patients suffering from monoclonal gammopathies. During its pathogenesis, HHV-8 might 
play a role in the formation of pathographies. HHV-4 is proportionately present in 
haematological pathographies. The data also indicate that in addition to HHV-8, the 
transient reactivation of HHV-4 might also play a role in the pathogenesis of monoclonal 
gammopathies. 
2. Epidemiology, diagnosis and prevention of human herpesviruses 
infections in hematologic diseases 
2.1 Human herpesvirus 1 (HHV-1) and human herpesvirus 2 (HHV-2)  
[Herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2)] 
Herpes simplex viruses were the first of the human herpesviruses to be discovered and are 
among the most intensively investigated of all viruses. Herpes simplex virus (HSV) was first 
isolated by Lowenstein (Lowenstein, 1919). The ability of HSV to establish a life-long latent 
infection in its human host is one of the most intellectually challenging aspects of HSV 
biology. 
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Herpes simplex virus (HSV) belongs to the Simplexvirus genus of the Alphaherpesvirinae 
subfamily of the Herpesviridae family. It has two serotypes, HSV-1 and HSV-2. It was 
classified into two serologically distinct types by Schneweiss (Schneweiss, 1962). HSV-1 and 
HSV-2 are phylogenetically ancient viruses that have evolved together with their human 
host (Davison, 2002). In humans, latent virus is reactivated after local stimuli such as injury 
to tissues innervated by neurons harboring latent virus, or by systemic stimuli (e.g., physical 
or emotional stress, hyperthermia, exposure to UV light, menstruation, or hormonal 
imbalance), which may reactivate virus simultaneously in neurons of diverse ganglia (e.g., 
trigeminal and sacral). 
Transmission of HSV depends on intimate, personal contact between a susceptible 
individual (namely, one who is seronegative) and someone excreting HSV. Thus, virus must 
come in contact with mucosal surfaces or abraded skin for infection to be initiated. 
Following oropharyngeal infection, usually caused by HSV-1, the trigeminal ganglion 
becomes colonized and harbors latent virus. Acquisition of HSV-2 infection is usually the 
consequence of transmission by genital contact. The epidemiology and clinical 
characteristics of primary infection are distinctly different from those associated with 
recurrent infection. HSV-1 causes acute gingivostomatitis, recurrent herpes labialis (cold 
sores), keratoconjunctivitis, blepharitis, iridocyclitis, encephalitis, tracheobroncitis, 
pneumonia, esophagitis, pharingitis, disseminalt infections, mucocutaneus lesions, herpetic 
whitlow, herpes gladiatorum, genital disease, neonatal infectio, and meningitis. HSV-2 
causes genital disease, anal and perianal infection, proctitis, neonatal herpes, meningitis, 
mucocutaneus lesions, herpetic whitlow, oral disease, keratoconjunctivitis, esophagitis, 
pharingitis, and encephalitis.  
A reappearance of HSV, known as recurrent infection, results in a limited number of 
vesicular lesions as occurs with HSV labialis or recurrent HSV genitalis. Reinfection with a 
different strain of HSV occurs, but it is uncommon in the normal host. Herpes simplex virus 
disease ranges from the usual case of mild illness, nondiscernible in most individuals, to 
sporadic, severe, and life-threatening disease in a few infants, children, and adults. 
Although HSV-1 and HSV-2 are usually transmitted via different routes and involve 
different areas of the body, much overlap is seen between the epidemiology and clinical 
manifestations of these two viruses. Historically, primary HSV-1 infections usually occurred 
in the young child, less than 5 years of age, and were most often asymptomatic. When the 
oropharynx is involved, the mouth and lips are the most common sites of HSV-1 infections, 
causing gingivostomatitis; however, any organ can become infected with this virus. Primary 
infection in young adults has been associated with only pharyngitis and a mononucleosis-
like syndrome (McMillan et al., 1993). Genital herpes can be caused by either HSV-1 or 2. As 
infections with HSV-2 are usually acquired through sexual contact, antibodies to this virus 
are rarely found before ages of onset of sexual activity. Recurrent HSV-2 infection, as with 
HSV-1, can be either symptomatic or asymptomatic. 
HSV-1 accounts for the majority of nongenital HSV-induced infections in humans, with 45% 
to 98% of the world population and 40% to 63% of the people in the United States reported 
HSV-1 seropositive (Ribes et al., 2001). Worldwide HSV-1 prevalence varies with age, race, 
geographic location, and socioeconomic status; a higher rate of seropositivity has been 
reported for less industrialized countries (Fatahzadeh & Schwartz, 2007; Chayavichitsilp et 
al., 2009). By the age of sixty, 60% to 85% of adults in the United States demonstrate HSV-1 
seroconversion. Incidence is not seasonal. Over the past thirty years, HSV-2 seroprevalence 
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has increased dramatically, with 20% to 25% of US adults tested positive for HSV-2 
antibodies by the age of forty (Fleming et al., 1997).  
Risk factors for HSV-2 infection include older age, female gender, black race, poor 
socioeconomic status, low level of education, prior sexually transmitted disease, early age at 
first intercourse, and a higher number of lifetime sexual partners (Corey & Handsfield, 
2000). Prepubertal detection of HSV-2 antibodies is rare. Prevalence of HSV2 seropositivity 
is strongly correlated with sexual maturity and promiscuity. Prevalence of HSV-2 antibodies 
is reported to be higher in women (Hettmann et al., 2008). 
Patients compromised by immunosuppressive therapy, underlying disease, or malnutrition 
are at increased risk of severe HSV infections. Renal, hepatic, bone marrow, and cardiac 
recipients are all at a particular risk of increased severity of transplant HSV infection. 
2.1.1 Epidemiology 
HSV-1 and HSV-2 commonly cause mucocutaneus lesions in patients with haematological 
malignancies, but HSV-1 is more frequent (Gnann, 2003). Up to 80% of adult patients with 
leukemia are HSV seropositive. The rate of HSV reactivation among HSV seropositive allo-Stem 
Cell Transplant recipients was reported to be approximately 80%, with the majority of these 
infections occurring during the first four weeks after transplant. They are also common, ranging 
from 15% among CLL (chronic lymphocytic leukemia) patients treated with fludarabine to 90% 
of patients with acute leukemia (Sandherr et al., 2006; Anaisse et al., 1998). Most individuals 
undergoing conventional chemotherapy are at low risk of HSV reactivation; however, those 
receiving T-cell depleting agents (e.g. fludarabine, alemtuzumab) or proteasome inhibitors are 
at high risk of reactivation of both HSV-1 and HSV-2 (Sandherr et al., 2006). 
The greatest risk of reactivation is seen in individuals with CD4 T-cell counts <50 cells/mm3, 
and other contribuiting risk factors are corticosteroid use, prolonged neutropenia, renal 
insufficiency, and age above 65 years. 
2.1.2 Clinical manifestations 
HSV reactivation in leukemic patients is usually associated with localizated mucocutaneous 
disease in the orofacial region (85-90%), and less frequently in the genital area (10-15%). The 
diagnosis of oropharyngeal HSV disease clinically can be difficult when severe mucositis is 
present. Mucositis and mucocutaneous ulcerations are common following high doses of 
chemotherapy, and occur at the same time as oral disease. Another frequent manifestation 
of HSV reactivations is esophageal disease. HSV esophagitis was found in about 10% of 
patients in studies of patients with leukaemia and other neoplastic disorders who had 
gastrointestinal symptoms. Uncommon HSV disease manifestations are pneumonia (2-3%), 
hepatitis, meningitis, and encephalitis (Kaufman et al., 1997; Angarone, 2011). 
Recurrent HSV infection is a major cause of morbidity and occasional mortality in the 
immunosuppressed patient who experiences frequent, persistent and severe recurrences of 
HSV-1 and HSV-2 infection. 
2.1.3 Monitoring and laboratory diagnosis of HSV infections 
An important characteristic of modern diagnostic virology is the use of multiple methods 
for detecting viral infections. These include viral isolation in culture, cytologic staining for 
viral infection with the Tzanck smear (Tzanck & Aron-Brunietiere, 1949), detection of viral 
antigens, nucleic acids, and viral antibodies, which are all used to diagnose current viral 
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infection. Light microscopy is used to detect the effect of viral infection in tissue and to 
define the role of viral infection in producing disease. Clinicians may wish to utilize 
laboratory tests to establish definitive diagnosis when clinical presentation of HSV 
infections is atipical. Virus isolation remains the definitive diagnostic method; however, 
polymerase chain reaction (PCR) detection of viral DNA is gaining increased acceptance 
even for routine skin infections. If skin lesions are present, skin vesicles should be scraped 
and transferred in appropriate virus transport media to a diagnostic virology laboratory. 
Virus may be isolated from various samples including skin lesions, cerebrospinal fluid 
(CSF), ocular fluid, swabs from mucocutaneous lesions, blood, stool, urine, throat, 
nasopharynx, conjunctivae and cornea. The experience with PCR indicates that it is an 
especially useful tool for diagnosis of HSV encephalitis in cerebrospinal fluid (CSF). 
The Tzanck smear is a rapid and reasonably priced diagnostic test that can confirm the 
presence of HSV infection. Although the test can confirm the presence of HSV or VZV, it 
cannot differentiate between the two herpes simplex serotypes and, therefore, cannot 
diagnose HSV-1 or HSV-2 infection definitively. The Tzanck smear has decreased in 
popularity as a diagnostic alternative to the direct fluorescent antibody assay (DFA) 
technique. In addition, DFA may be employed to serotype the HSV infection. Because DFA 
testing is rapid, inexpensive, and virally selective, it is often used to substantiate clinical 
suspicion and determine serotype. The biopsied cells are observed microscopically to detect 
degenerative cytopathologic changes commonly associated with the infection. The 
degenerative changes present in cells infected with HSV-1 and HSV-2 also are observed in 
cells infected with VZV. Thus, the specificity of the technique is low, and it cannot be used 
to serotype the infection. 
As HSV PCR becomes more readily available and less expensive, it has the potential to 
become the most widely used means of detecting HSV for all types of infection because it 
is rapid, highly reliable, and valid. Serologic assay is employed to detect the presence of 
HSV antibodies when other techniques are impractical or ineffective. Such assay takes 
longer to complete than other techniques and should be considered primarily for 
diagnosing recurrent infections, in the presence of healing lesions and the absence of 
active lesions, or when partners of a person who has clinical herpes are at risk. Sera are 
collected at two sepatate times. Acute serum is obtained within three to four days after the 
onset of initial symptoms, and convalescent serum is gathered several weeks after the 
symptoms have abted. To confirm a diagnosis of primary HSV infection, the acute sample 
should be devoid of HSV-positive antibodies due to the delayed humoral response, and 
the convalescent sample should demonstrate the presence of both immunoglobulin G and 
M antibodies to HSV proteins. If any quantities of antibodies are observed in the acute 
sample, primary infection is ruled out and the diagnosis is recurrent herpes infection. 
Measurement of antiviral antibodies was one of the first methods used for the specific 
diagnosis of viral infections and it remains an important tool in the diagnostic virology 
laboratory.  
The role of serology can be for the diagnosis of acute or current infection or for the 
determination of immune status to specific viruses. Serologic diagnosis of HSV infection is 
clinically valuable in the counseling of patients. Therapeutic decisions do not depend on the 
results of serologic studies. Immunoglobulin M (IgM) and IgG humoral responses have been 
well characterized. Antibodies [as detected by immunofluorescence assay (IFA), Enzyme 
immunoassay (EIA), enzyme-linked immunosorbent assays (ELISA)] are specific for HSV. 
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Serological tests are used for identification of seropositive patients before chemotherapy or 
hematopoietic stem cell transplantation (HSCT), but are not helpful in confirming the 
diagnosis of HSV reactivation. Routine surveillance for HSV reactivation could be done by 
culture or PCR, single (sPCR), nested PCR (n-PCR) and real-time or quantitative PCR (RT-
PCR or Q-PCR). PCR for HSV DNA in CFS is indicated in the diagnosis of HSV meningitis 
and encephalitis. 
2.1.4 Prevention of HSV diseases 
Vaccination remains the ideal method for prevention of viral infection; however, prevention 
of HSV infections introduces unique problems because of recurrences in the presence of 
humoral immunity. Nevertheless, protection from life-threatening infection can be achieved 
in animal models with avirulent, inactivated, or subunit glycoprotein vaccines, each of 
which has unique differences. Future study of the immune response induced by natural 
HSV infections in both adults and neonates is needed to provide insight into the 
requirements for vaccination against acute disease and recurrences. Attempts to produce an 
effective vaccine against HSV have been largely unsuccessful. Perhaps a most effective 
vaccine will be needed to stimulate most, if not all, key parameters of innate and adaptive 
immunity, both systematic and mucosal (Jones & Cunningham, 2004; Stanberry, 2004). 
HSV seronegative patients should attempt to prevent exposure to HSV. Early studies of 
intravenosus acyclovir in hematopetic stem cell transplantation recipients clearly 
documented its clinical efficacy: 0% to 2.5% of patients treated with acyclovir versus 50% to 
70% of those treated with placebo developed HSV lesions (Lundgren et al., 1985; Angarone 
& Ison, 2008). 
HSV seropositive patients: Based on the data, most cancer centers routinely use antiviral 
prophylaxis against HSV reactivation for leukemia patients' chemotherapy, especially those 
at high risk of ractivation such as those treated with purine analogs or alemtuzumab 
(Styczynski et al., 2009). Antiviral agents are routinely used as prophylaxis against HSV 
reactivation, using either i.v. acyclovir, oral acyclovir or valacyclovir, until three–five weeks 
after chemotherapy has been stopped (Angarone, 2011). 
2.1.5 Therapy of HSV diseases 
Advances in the treatment of HSV infections have led the way in the development of 
antiviral therapeutics. In the 1970s, vidarabine (adenine arabinoside) became the first 
licensed antiviral therapeutic for the treatment for herpes simplex encephalitis and neonatal 
HSV infections. Quickly, however, vidarabine was replaced by acyclovir in the the treatment 
of all HSV infections. Today acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, 
valganciclovir, cidofovir and foscarnet are the most useful and widely used therapeutics for 
the treatment of HSV-1 and HSV-2 infections (Knipe & Howley, 2007; Gilbert et al., 2010; 
Jancel & Penzak, 2009; Angarone, 2011). 
2.2 Human herpesvirus 3 (HHV-3) [Varicella-zoster virus (VZV)] 
Varicella-zoster virus (VZV) is a human alphaherpesvirus, which belongs to the 
Varicellovirus genus of the Alphaherpesvirinae subfamily of the Herpesviridae family. It causes 
varicella, commonly called chickenpox, during primary infection. Varicella, which is 
characterized by fever and a generalized, pruritic vesicular rash, is most prevalent in 
childhood. Varicella is highly contagious, producing annual epidemics among susceptible 
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individuals during winter and spring in temperate climates. Among the alphaherpesviruses, 
VZV is unique in its tropism for T lymphocytes, which allows dissemination of the virus to 
skin. VZV also infects and establishes latency in cells of the dorsal root ganglia. Its 
reactivation from latency produces herpes zoster, commonly referred to as shingles, an 
illness observed most often in older adults and immunocompromised patients of any age. 
The vesicular rash of herpes zoster is largely confined to regions of the skin served by a 
single sensory dermatome. Unlike varicella, herpes zoster infections are associated with 
acute pain that can be severe and prolonged. Pain that persists after the onset of herpes 
zoster for more than 30 days is called postherpetic neuralgia (PHN). 
Varicella and herpes zoster were described in very early medical literature. Once thought to 
be the same disorder, Heberden distinguished smallpox and varicella as two diseases in 
1867. In 1892, Bokay suggested an infectious etiology for varicella and herpes zoster and 
postulated that they were related (von Bokay, 1909), an idea supported by the 
demonstration that varicella occurs in children following inoculation with vesicular fluid 
from herpes zoster lesions and that virions from varicella and herpes zoster vesicle fluids 
are identical in appearance by electron microscopy (Almeida, 1962). The isolation of VZV in 
tissue culture was reported by Weller in 1953 (Weller, 1953). Primary VZV infection is 
presumed to be initiated by inhalation of respiratory droplets or by contact with infectious 
vesicular fluid from an infected individual. The potential for aerosol transmission is 
suggested by epidemiologic reports, and VZV DNA is detected in air samples from rooms 
occupied by patients with varicella or disseminated herpes zoster (Sawyer, 1994). 
Varicella-zoster virus latency is established during primary infection. VZV persists in 
sensory nerve ganglia. VZV can access neural tissues, either hematogenously or by 
centripetal neural transport from mucocutaneous lesions. 
Varicella-zoster virus reactivation, although possibly asymptomatic at times, typically 
presents as herpes zoster, a vesicular rash that is usually confined to the dermatomal 
distribution of a single sensory nerve. Because herpes zoster is caused by the reactivation of 
latent virus, susceptibility requires previous primary VZV infection. Given the high 
incidence of varicella, most adults are at risk of VZV reactivation. Herpes zoster is rare in 
childhood, but varicella during the first year of life, or VZV infection acquired by 
intrauterine transmission, are associated with an increased risk. 
The attack rate for previously uninfected household or day care center contacts exposed to 
varicella is about 90%. Varicella pneumonia in healthy adults presents with fever, cough, 
tachypnea, and dyspnea and may be associated with cyanosis, pleuritic chest pain, or 
hemoptysis. Varicella pneumonia is often transient, resolving completely within 24 to 72 
hours, but interstitial pneumonitis with severe hypoxemia progresses rapidly to cause 
respiratory failure in severe cases. 
Varicella hepatitis can occur subclinically, although it may be associated with severe 
vomiting. Aspirin is contraindicated in children with varicella because it predisposes to liver 
damage (Reye's syndrome). Patients with encephalitis typically have a sudden onset of 
seizures and altered sensorium, whereas those with cerebellar disease show a gradual 
progression of irritability, nystagmus, and gait and speech disturbances. Some patients have 
fever, headache, and meningismus, only without any altered consciousness or seizures. 
Acute thrombocytopenia causes petechiae and purpuric skin lesions, hemorrhage into the 
varicella vesicles, epistaxis, hematuria, and gastrointestinal bleeding. Hemorrhagic 
complications are usually transient. Purpura fulminans, caused by arterial thrombosis and 
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hemorrhagic gangrene, is a rare but life-threatening complication. Postinfectious 
thrombocytopenia occurs from 1 to 2 weeks or longer after varicella. Varicella nephritis 
causes hematuria, proteinuria, diffuse oedema, and decreased renal function, with or 
without hypertension. A few cases of nephrotic syndrome and hemolytic-uremic syndrome 
have been reported in children with varicella. Varicella arthritis is rare; it resolves 
spontaneously, with no residual joint disease. Other unusual complications of varicella 
include myocarditis, pericarditis, pancreatitis, and orchitis. Varicella vesicles are common 
on eyelids and conjunctivae, but eye disease is unusual. 
Reactivation of VZV in the trigeminal ganglion can produce ophthalmic disease, including 
conjunctivitis, dendritic keratitis, anterior uveitis, iridocyclitis with secondary glaucoma, 
and panophthalmitis. Loss of vision associated with herpes zoster is predominantly caused 
by retrobulbar neuritis and optic atrophy.  
2.2.1 Epidemiology 
The high incidence of herpes zoster in elderly and immunocompromised patients suggests 
that waning host immune responses to the virus have a significant impact on whether 
reactivation occurs and whether it will lead to symptomatic disease. Herpes zoster in young 
children after intrauterine or early postnatal varicella and the short interval between 
primary and recurrent VZV infections in children with HIV infection probably reflect their 
development of suboptimal cell-mediated immunity. Diminished in vitro T-cell proliferation 
to VZV antigens in elderly patients and in patients receiving immunosuppressive therapy 
correlates with higher susceptibility to herpes zoster.  
The incidence of VZV infection ranges from 2% among patients with chronic myelogenous 
leukemia (CML) receiving imatinib mesylate, to 10-15% in patients with chronic 
lymphocytic leukemia (CLL) receiving flurdarabine or alemtuzumab, to 25% of patients 
with Hodgkin lymphoma, myeloma treated with bortezomib or autologous stem cell 
transplant recipients, and to 45-60% among allogenic stem cell transplant recipients 
(Locksley et al., 1985; Anaisse et al., 1998; Sandherr et al., 2006; Wade, 2006). Infection risk is 
the greatest within the first twelve months following treatment or transplant. The majority 
of VZV infections in adult patients with a hematological malignancy are reactivation 
infections and 80% with localized disease (Locksley et al., 1985). After exposure to an 
individual with VZV infection (varicella or herpes zoster) seronegative leukemia patients 
and HSCT recipients are at risk of developing varicella, wich can be very severe. After 
HSCT, the risk of varicella is the highest in the first 24 months, or beyond this time if 
undergoing immunsuppressive therapy and having chronic graft-versus-host-disease 
(GVHD). Other risk factors include the pretransplantant diagnosis of leukemia and other 
lymphoproliferative disorders. 
2.2.2 Clinical manifestations 
Varicella manifests as a generalized, pruritic, vesicular rash. In leukemic patients and in 
those following HSCT, there is a risk of progressive severe varicella characterized by 
continuous eruptions of lesions, high fever, visceral dissemination, encephalitis, hepatitis, 
pneumonia, nausea, vomiting and diarrhea. Hemorrhagic varicella may sometimes occur. 
In herpes zoster, grouped painful vesicular lesions appear in the distribution of one to three 
dermatomes in the immuncompetent patients. In leukemia patients and HSCT recipients, 
varicella zoster may disseminate to several more dermatomes or throughout the whole 
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body, with the risk of visceral involvement, which may prove fatal. This visceral 
dissemination may sometimes occur without skin vesicles, which makes diagnosis difficult. 
2.2.3 Laboratory diagnosis 
Laboratory diagnosis is not necessary for the clinical management of most VZV infections in 
the immunocompetent host, but rapid diagnostic techniques are useful to guide decisions 
about antiviral treatment, especially for high-risk patients.  
The differentiation of the VZV infections from HSV and bullous dermatitis is an important 
indication for virological diagnosis. VZV infections of pregnant women and of newborn 
infants, atypical infections of immunodeficient patients, and suspected VZV infections of the 
central nervous system must be confirmed by laboratory diagnosis.  
VZV can be isolated in tissue culture, but it is not as easy as for HSV. Tzanck smear cannot 
differentiate between HSV and VZV. Nucleic acids are readily detected by PCR and 
detection of VZV antigens by immunohistochemical assays of cells from cutaneous lesions 
allows rapid diagnosis. The most sensitive methods are the fluorescent-antibody membrane 
antigen assay (FAMA) (Gershon et al., 1999). Latex agglutination methods provide a useful, 
sensitive alternative to FAMA (Steinberg & Gershon, 1991).  
Assays for VZV IgG antibodies are most useful for determining the immune status of 
individuals whose clinical history of varicella is unknown or equivocal. The enzyme-linked 
immunosorbent assay (ELISA) and the immunfluorescence technique are especially suited 
for the detection of VZV specific immunglobulin of classes IgG, IgM and IgA. Detection of 
IgM and high titered IgA anti-VZV antibodies usually indicates a reactivated VZV infection 
regardless of whether lesions are visible or not (Gross et al., 2003). 
PCR techniques (sPCR, n-PCR, RT- PCR or Q-PCR) for VZV DNA are considered the best 
diagnostic tools because they are very specific and sensitive and can detect viral DNA in 
vesicle samples, crusts, and throat swabs from patients with varicella or herpes zoster. PCR 
can be used for tissue specimens as well. VZV encephalitis following HSCT is diagnosed by 
PCR of cerebrospinal fluid. PCR of blood samples (serum, plasma) can document VZV DNA 
viremia in an HSCT recipient with herpes zoster, and quantitative monitoring (RT-PCR or 
Q-PCR) of circulating VZV DNA may be useful for the diagnosis and for assessing the 
response to treatment of visceral VZV infection without skin manifestation. PCR can also 
distinguish vaccine strain from wild-type VZV in clinical specimens (Kalpoe et al., 2006). 
2.2.4 Prevention 
The live attenuated Oka varicella vaccine is the first human herpesvirus vaccine licensed for 
clinical use in several countries. Its development and initial clinical evaluation were first 
reported by Takahashi in 1974 (Takahashi et al., 1974). The vaccine virus derived from a 
clinical isolate of VZV, the Oka strain; was isolated from a healthy Japanese child with 
varicella and atteunated by serial passage in cell culture; initially propagated in guinea pig 
embryo fibroblasts, and then in WI38 human cells. Clinical studies in Japan demonstrated 
the safety, immunogenicity, and clinical efficacy of Oka vaccine, which protected 
susceptibile immuncompetent and immuncompromissed children against varicella, even 
when administered shortly after exposure. Oka vaccine also boosted VZV specific cell-
mediated immunity in immunocompetent and immunocompromised adults. Varicella 
vaccine (Varivax; Merck) was licensed by the US Food and Drug Administration (FDA) in 
1995. Zoster vaccine (Zostavax; Merck) was licenced by the FDA in 2005. Recent 
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development of genetic analysis of VZV Oka strains isolated from vaccine-associated rashes 
and cases of herpes zoster may help identify specific single nucleotid polymorphisms 
(SNPs) that differentiate Oka vaccine from wild-type strains of VZV, and which contribute 
to attenuation of the vaccine and the pathogenicity of wild type VZV (Oxman, 2010). 
Oka vaccine is the most attenuated of all currently licensed live, attenuated virus vaccines, 
and it has been safely administered to VZV-susceptible children and VZV-seropositive 
children and adults, including susceptible children with human immunodeficiency virus 1 
infection and leukemia. Oka vaccine strain of VZV is fully susceptible to acyclovir, 
famciclovir, and valacyclovir; thus, effective antiviral therapy is available if complications 
involving vaccine virus replication occur. 
Inactivated zoster vaccines for administration to immuncompromised patients are 
potentially beneficial. Heat-inactivated VZV vaccine has been safely administrated to 
autologous bone marrow transplant recipients, in whom it accelerated recovery of VZV-cell 
mediated immunity and reduced the occurence of herpes zoster (Hata et al., 2002). 
Encouraged by these results, several groups are exploring the development of inactivated 
VZV vaccines, with and without adjuvants, to permit immunization of profundly 
immunsuppressed patients. 
2.2.4.1 Passive antibody prophylaxis 
Varicella zoster immune globulin (VZIG) and the related product are made from high-titer 
immune human serum. VZV antibody prophylaxis is recommended for passive 
immunization of individuals at high risk of serious varicella who were recently exposed to 
people with acute varicella or herpes zoster.  
2.2.4.2 VZV seronegative patients 
Fortunately, VZV can be prevented by minimizing exposure, passive immunization, and 
antiviral prophilaxis. VZV seronegative family members and contacts of HSCT candidates 
should be vaccinated against VZV no later than four weeks before conditioning begins. Contact 
with patients after vaccination must be avoided, especially if post-vaccination eczema occurs. In 
VZV seronegative patients, who have been in contact with varicella or herpes zoster and hence 
potentially contagious, airborne precautions should be instituted seven days after the first 
contact and continued until 21 days after the last exposure or 28 days post-exposure if the 
patient received passive immunization against VZV (VZIG-varicella-zoster immune globulin or 
ZIG-zoster immune globulin). Prior to the start of chemotherapy, VZV serologies should be 
evaluated and, if negative, exposure should be minimized. The role of direct prophylaxis and 
duration of that has yet to be tested in clinical trials (Wade, 2006; Styczynski et al., 2009). 
2.2.4.3 VZV seropositive patients 
Most HSCT recipients are VZV seropositive, following varicella in their childhood or 
following immunization with varicella vaccine, and are at risk of virus reactivation. There 
have been several retrospective studies of the use of acyclovir prophylaxis to prevent VZV 
reactivation in HSCT recipients. Arguments for the use of passive immunisation for VZV-
seropositive leukemia and HSCT recipients include the theoretical potential for 
supplementing immunity against VZV. The arguments against include scarity of VZIG and 
ZIG, their cost, the low incidence of reinfection, lack of proven efficiency in VZV-
seropositive recipients, and the possible adverse effect and discomfort associated with 
passive immunization (Weinstock et al., 2004). 
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2.2.5 Therapy 
Treatment of VZV disease should include the early institution of antiviral therapy 
(valacyclovir, acyclovir or famciclovir). Acyclovir therapy diminishes the clinical severity of 
varicella in immunocompromised children by ensuring that cell-associated viremia is 
terminated efficiently despite the impaired host response. Early antiviral therapy prevents 
progressive varicella and visceral dissemination. Acyclovir and valacyclovir are highly 
effective. Yet, despite its efficiency in preventing disease, antiviral prophylaxis is not 
routinely recommended by many of the clinical care guidelines (Sandherr et al, 2006). 
In addition to preventing life-threatening dissemination, early acyclovir therapy minimizes 
cutaneous disease, which may reduce the risk of secondary bacterial infections. 
Immunocompromised patients who have pneumonia, hepatitis, thrombocytopenia, or 
encephalitis require immediate treatment with intravenous acyclovir. Oral acyclovir can be 
used to diminish varicella symptoms in healthy children, adolescents, and adults when 
administered within 24 hours after the appearance of the initial cutaneous lesions. Adults 
with varicella pneumonia, including pregnant women, require immediate treatment with 
intravenous acyclovir. Acyclovir is effective for the treatment of recurrent VZV infection in 
healthy and immunocompromised patients. Among healthy individuals, the period of 
continued new lesions in the involved dermatome was shortened, as was the time to 
complete healing.  
Acyclovir treatment is especially important in patients who are immunocompromised 
because of their risk of disseminated disease, and it is important in healthy adults with 
ophthalmic zoster because of their risk of developing acute uveitis and chronic keratitis. 
Acute neuropathic pain is reduced by early treatment with acyclovir, valacyclovir, or 
famciclovir, but effects on rates of subsequent PHN are less obvious. Acyclovir is given 
intravenously to immunocompromised patients who are at high risk of disseminated 
disease. Daily acyclovir (or suitable alternative) appears to be effective at preventing herpes 
zoster virus in patients with myeloma who are receiving bortezomib, with or without 
corticosteroids (Vickrey et al., 2009). Acyclovir prophylaxis effectively prevented VZV 
disease after allogenic transplantation. This regimen is highly effective, safe, inexpensive, 
and does not appear to interfere with VZV specific immune reconstruction (Boeckh et al., 
2006). At present, acyclovir prophylaxis is not a universal practice in all transplant centers, 
because the prompt initiation of acyclovir for the treatment of recurrent VZV infections is 
effective (Weinstock et al., 2004) and long-term use can be associated with emergence of 
drug-resistant VZV mutants. 
2.3 Human herpesvirus 4 (HHV-4) [Epstein-Barr virus (EBV)] 
The discovery of Epstein-Barr virus (EBV) by Epstein, Achong, and Barr, reported in 1964 
(Epstein et al., 1964), was stimulated by Denis Burkitt’s recognition of novel African 
childhood lymphoma and his postulation that an infectious agent was involved in the tumor 
etiology. Human herpesvirus 4 (HHV-4 or EBV) was classified as belonging to the 
Lymphocryptovirus genus within the subfamily Gammaherpesvirinae of the Herpesviridae 
family. With respect to biology, it causes two types of infection: primary infection, mainly in 
children and adolescents, and reactivation of latent infection. The syndrome caused by 
primary infection includes infectious mononucleosis, chronic active EBV infection and X-
linked lymphoproliferative syndrome. Most EBV reactivations are subclinical and require 
no therapies; however, it may be manifest as encephalitis, myelitis, pneumonia, and 
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hepatitis. HHV-4 associated tumors (reactivation syndromes) include lymphoproliferative 
disease (LPD), Burkitt’s lymphoma, non-Hodgkin’s lymphoma, nasopharyngeal carcinoma, 
natural killer (NK)-cell leukemia, Hodgkin’s disease, hemophagocytic lymphohistiocytosis, 
and angioblastic T-cell lymphoma (Ambinder, 2007; Delecluse et al., 2007). 
2.3.1 Epidemiology 
EBV infection occurs in more than 90% of the normal population, and immuncompromised 
patients are predominantly at risk of disease due to EBV reactivation. The incidence of 
PTLD (post-transplant lymphoprolifertaive disease) varies with the organ transplanted, and 
ranges from 1% for renal to 14% small bowel transplant recipients. 
2.3.2 Clinical manifestations 
A significant number (at least 25%) of serologically confirmed primary infections in 
adolescence or early adult life are manifested as infectious mononucleosis, as they are a 
small number of infections in childhood. Symptoms can range from mild transient fever to 
several weeks of pharyngitis, lymphodenopathy, and general malaise. The period of acute 
disease correlates much more closely with that of CD8 T lymphocytosis than with high virus 
shedding and, indeed, treating patients using infectious mononucleosis with oral acyclovir 
to block virus shedding brings little if any clinical benefit. 
The main manifestation of EBV infection after allogenic HSCT is the development of post-
transplant lymphoprolifertaive disease (PTLD) in the presence of reactivated infection, 
which has a very poor prognosis. The clinical manifestation of EBV-associated PLTD may 
include fever, lymphadenopathy, tonsillitis, hepatosplenomegaly, and symptoms and signs 
from other affected organs. Although the incidence is low (0.5-2.0 %), it may rise as high as 
20% in the presence of three or more risk factors. The morbidity risk is highest during the six 
months post HSCT (Islam et al., 2010). Risk factors for developing EBV related PLTD are: ex 
vivo T-cell depletion, treatment with antithymocyte globulin for preventing or treating 
GVHD, anti–CD3 antibodies for GVHD therapy, and unrelated or HLA-mismatched 
transplant. 
2.3.3 Laboratory diagnosis 
Viral detection and in situ hybridization techniques fall into the former category whereas 
immunohistochemistry is useful for distinguishing latent from replicative infection and for 
identifying the prevailing from of EBV latency. Fluorecence in situ hybridisation (FISH) is 
the method of choice for visualisation of viral nucleotide sequences in the infected cells, 
interphase nuclei or on chromosomes (Wilson & May 2001). Using PCR with this sensitivity 
can be used to quantitate absolute numbers of infected cells in a given population. Virus can 
be isolated on cell line.  
The serologic profile, therefore, can be a useful marker of past infection. Because patients 
who are B-cell deficient do not naturally acquire EBV, we have no direct information from 
clinical observation about the biological importance of the antibody response. Antibodies to 
VCA, EA, and the EBNAs target intracellular antigen complexes and, therefore, seem 
unlikely to play any major effector role in controlling virally infected cells in vivo. 
EBV reactivation prospective monitoring of EBV viraemia by Q-PCR is recommended after 
high risk allo HSCT. Screening for EBV DNA should start at the day of HSCT, and last for 
three months with frequency of at least once a week in high-risk cases. 
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Diagnosis of LPD or PTLD must be based on symptoms and/or signs consistent with 
lympoproloferative processdeveloping after HSCT, together with detection of EBV by an 
appropriate method applied to specimen from the involved tissue. EBV detection in a 
biopsy specimen requires detection of viral antigen or in situ hibridization for the EBER 
(Epstein-Barr-encoded RNA).  
2.3.4 Prevention 
The sheer range of EBV-associated diseases emphasizes the importance of developing either 
prophylactic vaccines to reduce disease burden or therapeutic strategies that specifically 
target virus-positive lesions. A number of approaches are currently being pursued. The first 
clinical testing of a gp350-expressing recombinant viral vaccine, based on the Chinese Tien 
Tan strain of vaccinia virus, was carried out on small groups of EBV-seronegative and EBV-
seropositive children (Gu et al., 1995). Phase I and II trials of a gp350 subunit vaccine in 
young adults have induced a neutralizing antibody response; this did not prevent primary 
infection within the vaccinated group, but it did significantly reduce the incidence of 
infectious mononucleosis symptoms compared with the placebo controls. 
2.3.4.1 EBV seronegative patients 
Seronegative individuals should undertake behaviour that minimizes the likelihood of EBV 
exposure. If a patient is found seronegative, the risk of PTLD is higher. Also, HSCT donors 
should be tested before transplantation for EBV serology. When there is choice, the selection 
of a seronegative donor might be beneficial as EBV might be transmitted with the graft. 
Prevention of PTLD has focused on EBV DNA monitoring and use of the donor–derived 
cytotoxic T-cells. 
2.3.4.2 EBV seropositive patients 
Reactivation of EBV is common after allo-HSCT, but rarely causes significant problems 
through direct viral end-organ disease. The important complication of EBV replication is 
PTLD. Poor or negative data are available regarding EBV prophylaxis. Ganciclovir can 
reduce EBV replication, but neither ganciclovir and foscarnet nor cidofovir therapy and 
prophylaxis have any impact on the development of PTLD. 
2.3.5 Therapy 
Anti-CD20 antibodies (rituximab), reduction of immunsuppression or adoptive 
immunotherapy are recommended as a first-line therapy for PTLD. Four to eight doses of 
rituximab are needed to obtain clincal improvement and reduce the EBV DNA load. 
Chemotherapy is a second–line option.  
2.4 Human herpesvirus 5 (HHV-5) [Cytomegalovirus (CMV)] 
Human herpesvirus 5 (HHV-5 or CMV) was classified as belonging to the 
Cytomegalovirus genus within the subfamily Betaherpesvirinae of the Herpesviridae family. 
The virus usually infects the population in early childhood, and later, at the time of 
sexual activity. The primary infection of immuncompetent patients is generally 
symptomless, or causes self-limiting diseases, such as certain cases of infectious 
mononucleosis. The primary CMV infections of seronegative pregnant women's 
transplacental transmission during pregnancy leading to fetal damage may cause severe 
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congenital damage in the neonates, including deafness and mental retardation. 
Reactivation or primary CMV infection in immunocompromised patients can give rise to 
a wide range of complications in many organs of the host. Ho provides a comprehensive 
summary of work leading to the recognition of CMV as a separate medically important 
herpesvirus subfamily (Ho, 1991).  
By the early 1950s, cytomegalic inclusion disease was diagnosed based on the presence of 
inclusion-bearing cells in urine, and viral etiology was predicted based on the detection of 
approximately 100 nm viruslike particles with low-resolution electron microscopy (EM). The 
unrelenting efforts of Margaret Smith, which led to isolation of this virus from urine of 
congenitally damaged newborns, followed her earlier success isolating the related mouse 
salivary gland virus (now called murine CMV) commonly used a viral strain that bears her 
name (Knipe & Howley, 2007). As with all herpesviruses, CMV latency is likely to be 
maintained in everyone who experiences primary infection. The propensity of virus to 
reactivate following immunosuppression or immunodeficiency is an important factor 
leading to CMV-associated diseases. CMV also remains medically prominent as an 
opportunistic infection in the immunocompromised host and this drives initiatives for 
therapeutic intervention. 
CMV reactivation remains a significant cause of morbidity and mortality due to the 
extended period of immunodeficiency after allogenis HSTC. The CMV status of the 
recipients before HSCT has strong influence on HSCT outcome (Zhou et al., 2009). 
2.4.1 Epidemiology 
CMV has a worldwide distribution and infects up to 50-85% of the population in 
industrialized countries. CMV is predictably transmitted in settings where susceptible 
persons have contact with body fluids from persons excreting virus. Transmission appears 
to require direct contact with infectious material; spread by the airborne route or through 
aerosols does not occur. Following initial acquisition of CMV, infectious virus is present in 
urine, saliva, tears, semen, and cervical secretions for months to years. Two types of 
exposures have consistently been linked with horizontal transmission of CMV: sexual 
activity and contact with young children. Vertical transmission from mother to fetus or 
newborn not only occurs but is common and plays an important role in maintaining 
infection in the population. In this context, CMV is spread by three routes: transplacental, 
intrapartum, and via human milk.  
Immuncompromised hosts are at elevated risk of serious CMV disease following primary 
infection, reinfection, or reactivation of latent virus (Sandherr et al., 2006). CMV is a 
leading infectious cause of morbidity and mortality in patients after HSCT and solid 
organ transplantation, and is an emerging problem in adults with leukaemia. CMV 
infection occurs in 60-70% of allogenic HSCT recipients when patient or donor are CMV 
seropositive, and is documented in about 50-60% of CMV seropositive autograph 
recipients. Other predisposing factors include the occurrence of acute GVHD, HLA-
mismatched transplant, and a positive CMV serology of the graft donor in seronegative 
patients (Ng et al. 2005). The majority of CMV infections occur during the first three to 
four months after transplant largely controlled by preventive strategies using antiviral 
drugs; CMV infection remains a significant problem in this setting because of 
breakthrough disease in high risk patients, late onset disease, and indirect effects that 
adversely affect outcome. 
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2.4.2 Clinical manifestations 
CMV infection is manifested clinically in the normal host. The illness is similar to 
mononucleosis that occurs with EBV infection. Estimates indicate that CMV is responsible 
for 20% to 50% of heterophile-negative mononucleosis and that it accounts for 
approximately 8% of all cases of mononucleosis. It is characterized by fever for more than 
10 days, malaise, myalgias, headache, and fatigue. Splenomegaly, hepatomegaly, 
adenopathy, and rash are present in some patients. Compared to EBV-induced 
mononucleosis, pharyngitis, adenopathy, and splenomegaly are noted less commonly 
with CMV. 
CMV disease manifestation includes pneumonia, enteritis, encephalitis, retinitis, hepatitis, 
cholangitis, cystitis, nephritis, sinusitis, and marrow suppression. CMV pneumonia was also 
increased among patients with lymphoma and acute leukemia. CMV-attributable mortality 
for these patients ranged from 30% to 60%. 
Primary CMV infection is when CMV is detected in a previously CMV seronegative patient. 
Recurrent CMV infection is when CMV is detected in a CMV seropositive patient. At 
symptomatic CMV infection, patients develop symptoms (fever with or without bone 
marrow suppression) and carry detectable CMV virions, antigens or nucleic acid, but with 
no sign of CMV endorgan disease. CMV disease is when CMV can be detected by test with 
appropriate sensitivity and specificity in an organ, in a biopsy, or in samples from other 
invasive procedures, bronco-alveolar lavage (BAL), cerebrospinal fluid (CSF) together with 
symptoms and/or sings from the affected organ. For CMV retinitis, typical findings by 
ophtalmologic examination are sufficient. 
2.4.3 Laboratory diagnosis 
Several techniques exist allowing rapid diagnosis of CMV with high sensitivity. Serologic 
tests for antibody to CMV are useful for determining whether a patient had CMV infection 
in the past, a determination of great clinical importance for organ and blood donors, and in 
the pretransplant evaluation of prospective transplant recipients. The avidity of IgG 
antibody increases with time after initial infection and demonstration of low CMV-IgG 
avidity can improve the accuracy of identification of recent primary infection. Antibody 
tests are not useful in the diagnosis of CMV disease in the immunocompromised host. 
Serology determination of either IgG or IgM has no place in the diagnosis of CMV infection 
or disease but is useful to determine the risk of subsequent CMV infection. The most 
commonly used tests for diagnosis of CMV infection are the detection of antigen (pp65 
antigenaemia assay), DNA, or mRNA. Use of a quantitative assay (Q-PCR) gives additional 
information valuable for patient management. CMV gastrointestinal disease is the 
combination of clinical symptoms, findings of macroscopic mucosal lesions on endoscopy, 
and demonstration of CMV by culture, histopathologic testing, immunohistochemistry or in 
situ hybridization in a biopsy specimen. PCR on biopsy material is insufficient for the 
diagnosis of CMV gastrointestinal disease. 
2.4.4 Prevention 
The different preventive strategies for CMV disease include the use of antiviral agents, such 
as chemoprophylaxis, pre-emptive therapy or treatment of symptomatic CMV infection. The 
currently available aniviral agents for prevention of CMV infection and disease are 
ganciclovir, valganciclovir, foscarnet and cidofovir (Ljungman et al.,2008). 
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CMV seronegative patients have low risk of contracting CMV infection. To reduce the risk 
of CMV transmission, blood product from CMV seronegative donors or leukocyte-depleted 
blood product should be used. CMV seronegative patients with CMV seronegative stem-cell 
donors have a lower risk of post transplant complications both from CMV and from the 
effect of CMV associated immunsuppression with its concomitant increased risk of bacterial 
and fungal infections. 
Hyperimmune globulin preparations with high levels of antibody to CMV (CMVIG) have 
been evaluated for prevention of CMV disease in organ transplant recipients, premature 
newborns at risk for postnatal infection and pregnant women. Although attempts to 
develop a vaccine for prevention of maternal and congenital CMV have been pursued for 
more than 25 years, no vaccine is currently licensed or near licensure. Improved 
understanding of the role of specific viral proteins in eliciting protective immune responses 
and recent recognition of the potential benefit to society and cost-effectiveness of CMV 
vaccines, however, are stimulating development of new vaccines. Investigational vaccines 
using different formats have been evaluated in clinical trials; these include attenuated live 
virus, a recombinant protein in a fowl pox vector, a DNA vaccine, and a recombinant 
protein given with a new adjuvant (Sung & Schleiss, 2010). 
2.4.4.1 CMV seropositive patients 
The use of preemptive monitoring for CMV reactivation in patients receiving 
alemtuzumab for at least two months following the receipt of chemotherapy is 
recommended. Once CMV reactivation is recognized, either oral valganciclovir or 
intravenous ganciclovir may be used. 
2.4.5 Therapy 
The four antiviral agents (Ganciclovir, Valganiclovir, Foscarnet, and Cidofovir) are currently 
approved for treatment of CMV disease (Fellay et al. 2005; Knipe & Howley, 2007). Antiviral 
agents are commonly used in transplant medicine to prevent CMV disease, either as a daily 
prophylactic regimen or in a preemptive approach in which laboratory surveillance for 
CMV in blood is used to identify patients for antiviral therapy (Reusser 2002). 
2.5 Human herpesvirus 6 (HHV-6) 
Human herpesvirus 6 (HHV-6) belongs to the Roseolovirus genus of the Betaherpesvirinae 
subfamily of the Herpesviridae family. HHV-6 was first isolated in 1986 from B-
lymphocytes of patients infected with HIV, HTLV, and lymphoproliferative disorders 
(Salahuddin et al., 1986). Because of tropism to B lymphocytes, the virus was first named 
human B-lymphotropic virus, but was later found mainly to infect and replicate in 
lymphocytes of the T-cell lineage. HHV-6 isolates are classified into two closely related 
groups, variants A (HHV-6A) and B (HHV-6B). HHV-6B is the major causative agent of 
exanthem subitum (roseola infantum), which is characterized by high fever, diarrhoea, 
and a mild skin rash along the trunk, neck, and face (Yamanishi et al., 1988). HHV-6A 
has been associated with several adult diseases, including cofactor in AIDS progression, 
and various neurological disorders including encephalitis, ataxia, seizure, liver 
disfunction, and chronic fatigue syndrome; however, the causal link between human 
diseases and virus infection remains to be fully elucidated (De Bolle et al., 2005; Ablashi 
et al, 2010).  
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Following primary infection, the genome of herpesviruses establishes latency as a nuclear 
circular episome. The in vivo and in vitro integration of HHV-6A and HHV-6B into the 
telomers of human chromosomaes during latency was demonstrated by Arbuckle et al. 
(Arbuckle et al., 2010; Arbuckle & Medveczky 2011). The integrate HHV-6 genome was 
also found to be vertically transmitted from parent to child in the germ-line. 
Characterisation of the integration sites in tumor samples and long-term follow up studies 
may elucidate the relationship between integration and leukemogenesis (Minarovits et al., 
2007) 
2.5.1 Epidemiology 
Seroprevalence of HHV-6 decreases at five months of age, as maternal antibody wanes. 
Beginning at about 6 months, seroprevalence increases rapidly, with almost all children 
becoming positive by 2 years of age. Internationally, HHV-6 seroprevalence is high in 
almost all areas, but ranges from approximately 39% to nearly 100% among some ethnically 
diverse adult populations. 
HHV-6 genomes and antigens are detectable in lymph nodes of patients with sinus 
histiocytosis with massive lymphadenopathy tubular epithelial cells, endothelial cells and 
histiocytes in kidney salivary glands and central nervous system tissues, where viral gene 
products have been localized to neurons and oligodendrocytes (Levine et al., 1992; Kurata et 
al., 1990). HHV-6 is also detected in lesions of Langerhans cell histiocytosis in the syndrome 
of Langerhans cell histiocytosis (Leahy et al., 1993; Csire et al., 2007a). 
2.5.2 Clinical manifestations 
Asymptomatic HHV-6 reactivation is common after allogeneic bone marrow transplantation 
(Cone et al.,1999), but reactivation has also been linked to bone marrow suppression, 
encephalitis, gastroduodenitis, colitis, pneumonitis, rash, and acute graft-versus-host 
disease, all of which have been reviewed by others (De Bolle et al., 2005). Liver dysfunction 
is also associated with HHV-6 infection; although usually mild, it can be fatal hepatitis and 
chronic hepatitis. Primary HHV-6 infection has also been associated with cases of idiopathic 
thrombocytopenic purpura. Further, human herpesvirus 6 infection has also been associated 
with pneumonitis, with the infected cells being primarily intraalveolar macrophages, plus 
some lymphocytes.  
Concentrations of HHV-6 genomes in lung tissue and their relation to changes in serologic 
titers support an association between HHV-6 infection and idiopathic pneumonitis in 
immunocompromised hosts. HHV-6 reactivates early after HSCT and is found in the 
blood in about half of all allo-HSCT recipients, making it difficult to make disease 
association. Two viral variants of HHV-6 have been identified (A and B), but the HHV-6B 
is most frequently associated with disease among immuncompromised patients. 
Longitudinal studies in HSCT recipients found the viral reactivation to occur at a median 
of 20 days after transplantation, and that viral shedding for some patients was prolonged, 
and correlated poorly with clinical improvement (Zerr et al., 2005). A clinical syndrome 
consisting of central nervous system dysfunction, impaired memory, secondary 
hypothyroidism, and delayed platelet engrafment are common disease manifestations. 
HHV-6 viraemia among allogenic transplant recipients is associated with the increase in 
all-cause mortality, and viraemia appears to be increased when patients are transplanted 
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for disease other than first remission, when donor and recipient are sex mismatched, and 
among younger patients. 
2.5.3 Laboratory diagnosis 
HHV-6 virus isolation is easily recovered from peripheral blood mononuclear cells of 
patients with exanthema subitum during the acute phase. Cytopathic effect (CPE) develops 
within 7 to 10 days. The refractile giant cells usually contain one or two nuclei and, after the 
occurrence of the CPE, lytic degeneration of the cells takes place. The rate of virus isolation 
from mononuclear cells was 100% on days 0 to 2 (just before appearance of skin rash), 82% 
on day 3, and 20% on day 4. 
Numerous HHV-6 serologic assays have been described, including IFA, ELISA, 
neutralization, and immunoblot. IFA is the most commonly applied method, with HHV-6 
infected cells being used as the antigens. For detection of IgM, separation of serum IgM 
from IgG and IgA significantly increases the specificity.  
Antigenemia tests: such tests have been used for the diagnosis of HHV-6 infection in blood, 
but there is limited experience as their use has not been widespread. 
HHV-6 DNA can be detected via PCR techniques (sPCR, n-PCR) from blood, cerebrospinal 
fluid (CSF), tissue samples, and other samples in view of the differing natural histories of 
variants A and B. Quantitative PCR (Q-PCR or real-time PCR) analysis on blood and CSF is 
the method of choice for diagnosis. 
Possibile techniques include in situ hybridization and immunohistochemistry, but these are 
not generally available. 
2.5.4 Prevention 
Antiviral prophylaxis against HHV-6: foscarnet, ganciclovir and cidofovir have been shown 
to inhibit HHV-6 replication. Data from two small non-randomized studies of HSCT 
recipients suggest that prophylactic gancyclovir can prevent recurrent HHV-6 infection 
(Tokimasa et al., 2002, Rapaport et al., 2002). 
2.5.5 Therapy 
Foscarnet and gancyclovir, alone or in combination, have been used as treatment for HHV-6 
infection. For treatment of HHV-6 encephalitis foscarnet or ganciclovir are recommended as 
first-line therapies after HSCT. Cidofovir is recommended as a second-line therapy. 
2.6 Human herpesvirus 7 (HHV-7) 
Human herpesvirus 7 (HHV-7) belongs to the Roseolovirus genus of the Betaherpesvirinae 
subfamily of the Herpesviridae family. HHV-7 was first described in 1990 (Frenkel et al., 1990). 
HHV-7 was isolated in 1990 from a healthy individual whose cells were stimulated with 
antibody against CD3 and then incubated with interleukin-2. The virus is one of the 
causative agents of exanthema subitum (Tanaka et al., 1994) and has been associated with 
febrile convulsions in young children (Ward et al., 2005). After primary infection of CD 4+T 
lymphocytes, HHV-7 infects (similar to HHV-6) epithelial cells of salivary glands and 
various organs (lungs, skin, mammary gland, liver, kidney and tonsils). HHV-7 could be 
reactivated from lately infected peripheral blood mononuclear cells by T-cell activation. 
Thus, HHV-7 can provide transacting functions, mediating HHV-6 reactivation from latency 
(Tanaka-Taya et al., 2000). 
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2.6.1 Epidemiology 
HHV-7 infection appears to occur slightly later than HHV-6. As for HHV-6, seroprevalence 
declines over the first 5 to 6 months, as maternal antibody wanes, then increases fairly 
rapidly up to 4 years of age. HHV-7 is ubiquitous, with more than 44%-91% of adults having 
antibody to virus.  
2.6.2 Clinical manifestations 
Although the frequency of clinical illness is lower, primary infection with HHV-7 causes 
illness similar to that of HHV-6, including exanthem subitum, high fever, and neurologic 
symptoms (e.g., febrile convulsions).  
In 1997, Drago et al. reported the association of pityriasis rosea with HHV-7 infection and 
proposed that it is a clinical presentation of HHV-7 reactivation. Peripheral blood 
mononuclear cell (PBMC) from patients with pityriasis rosea showed ballooning cells and 
syncytia after 7 days in culture, whereas PBMC from controls and patients recovered from 
pityriasis rosea did not. PCR identified HHV-7 DNA in PBMC, plasma, and skin from all 
patients with active pityriasis rosea, and only in the PBMC 10 to 14 months later. HHV-7 
detection after HSCT is relatively infrequent, and there are only a handful of cases in which 
HHV-7 is associated with central nervous system disease (Yoshikawa et al., 2003). 
2.6.3 Laboratory diagnosis 
HHV-7 is sometimes isolated from peripheral blood of patients with exanthema subitum, 
and can be readily isolated from saliva by using methods as described above for HHV-6. 
Isolation of HHV-6 from saliva is uncommon, although its DNA is often detectable there. 
HHV-7 serology techniques are immunoblot, IFA, and ELISA assays for HHV-7 antibodies. 
The ELISA was the most sensitive, whereas the immunoblot was the most specific. As 
mentioned, antibody avidity assays enable identification of recent primary infections (Ward 
2005). PCR techniques (sPCR, n-PCR, Q-PCR or RT-PCR) can be used to detect HHV-7 DNA 
of blood, cerebrospinal fluid (CSF), tissue, or other samples.  
2.6.4 Prevention 
In view of the limited data, no recommendations can be made regarding HHV-7 as a 
potential pathogen in leukemia patients or after HSCT. 
2.6.5 Therapy 
The majority of conditions due to infection do not require antiviral medication, but the severe 
complications may be treated with ganciclovir and its derivates or foscarnet and cidofovir.  
2.7 Human herpesvirus 8 (HHV-8) [Kaposi’s sarcoma associated herpesvirus (KSHV)] 
Kaposi's sarcoma associated herpesvirus (KSHV; human herpesvirus 8, HHV-8) is the most 
recently discovered human herpesvirus (Chang et al., 1994). Kaposi's sarcoma (KS) is a 
complex, angioproliferative and inflammatory lesion that was first described by Kaposi in 
the late 19th century (Kaposi, 1872). HHV-8 belongs to the Rhadinovirus genus of the 
Gammaherpesvirinae subfamily of the Herpesviridae family. HHV-8 is the ethiologic agent of 
Kaposi’s sarcoma, and has been implicated in other B-cell lymphoproliferative disorders 
including primary effusion lymphoma and a subset of multricentric Castleman disease. 
HHV-8 has been implicated in the pathogenesis of several other diseases, including multiple 
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myeloma, Waldenstörm macroglobulinaemia, and monoclonal gammopathy with unknown 
significance (Mikala et al., 1999).  
2.7.1 Epidemiology 
The prevalence of HHV-8 infection is very high in older children and adults in Africa and 
the Amazon basin (50-100%), medium in the Mediterranean (5-25%), and low in North 
America, North and West Europe (2-5%). Transmission of the virus is sexual; in homosexual 
and bisexual persons, seroprevalence rates are substantially lower among women than men. 
Transmission is possible via saliva in areas of high epidemicity. HHV-8 may be transmitted 
by blood transfusion and solid organ transplantation (Hladik et al., 2006). 
2.7.2 Clinical manifestations 
Transplant patients may acquire HHV-8 from the allograft, blood products, caregivers, or 
from family members. Cutaneuous or visceral Kaposi’s sarcomas develop with a reported 
incidence of 0.5-5.0% in solid organ recipients (Jenkins et al., 2002). 
2.7.3 Laboratory diagnosis 
The first successful cultivation of HHV-8 used PEL cell lines explanted from patients with 
advanced AIDS (Renne et al., 1996). HHV-8 diagnostic serology techniques may include 
immunoblot, IFA, and ELISA assays for HHV-8 antibodies (Sarmati 2001; Juhasz et al., 
2001). These are useful for donors and recipients in at risk population, but wherever 
available, are of variable sensitivity and specificity (Sergerie et al., 2004). 
HHV-8 DNA can be detected via PCR techniques (sPCR, n-PCR, Q-PCR or RT-PCR) from 
the whole blood, plasma or serum, cerebrospinal fluid (CSF), tissue or other samples. 
Possible techniques may include in situ hybridization and immunohistochemistry, but these 
are not generally available. 
2.7.4 Prevention 
In view of the limited data, no recommendations can be made regarding HHV-8 as a 
potential pathogen in leukemia patients or after HSCT. 
2.7.5 Therapy 
Antiviral agents that target herpesvirus DNA synthesis, such as ganciclovir, foscarnet and 
cidofovir, inhibit HHV-8 lytic replication and can prevent Kaposi sarcoma (Cohen & 
Powderly 2004). Several HIV protease inhibitors may interfere with tumor growth and 
angiogenesis, and one protease inhibitor, nelfinavir, directly inhibits HHV-8 replication in 
vitro (Gantt & Casper, 2011). 
3. Conclusion 
The spectrum of viral infections for patients with haematological diseases is expanding and 
diagnosis has increased because of new molecular diagnostic techniques. The group of human 
herpesviruses consists of eight members. Primary and reactivation infections are characteristic 
of these pathogens. Viral latency can be predicted by serological screening and it is useful for 
disease management. Antiviral therapy is now routinely used for prevention and therapy. Viral 
immunization remains investigational, except for the VZV vaccination (Cheuk et al., 2011).  
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Human herpesviruses are a major cause of related morbidity and mortality in hematologic 
diseases. This chapter focuses on the epidemiology and prevention strategies for human 
herpesviruses in this population (see Table 1.). 
 
Virus 
Disease 
---------------------
Population 
Surveillance
-----------------
(Monitoring)
Recommended 
antiviral agent
Preventative 
measure 
Timing and 
Duration 
HHV-1 & 
HHV-2 
(HSV-1 & 
HSV-2) 
Reactivation, 
rare first 
infection 
Mucositis 
Esophagitis 
Pneumonitis or 
hepatitis Baseline 
serologies 
 
Prophylaxis if 
seropositive
-----------------
(No) 
ACV 
GCV 
VACV 
VGCV 
FAM 
Prophylaxis: 
IV ACV 
5mg/kg BID 
oral ACV 
200mg TID 
oral VACV 
500mg BID 
Initiate 
prophylaxis 
with start of 
chemotherapy 
Continue for 3-
5 weeks post-
chemotherapy 
HSCT 
ACV 250mg 
per meter-
squared IV 
q12h or oral 
ACV 200mg 
TID 
oral VACV 
500mg BID 
FAM 750 mg 
po q24h or 
500mg BID or 
250mg TID 
at least 30 days 
post-
tranplantation 
Leukemia 
during 
neutropenia 
Alemtuzumab 
therapy 
2 months after 
therapy or 
until CD4> 100 
cells/ul 
HHV-3 
(VZV) 
Primary 
infection 
varicella, 
reactivation 
herpes zoster 
Baseline 
serologies 
 
preventative 
therapy if 
seronegative
ACV 
GCV 
VACV 
VGCV 
FAM 
post-exposure 
prophylaxis 
ACV 
800mg QID, 
VACV 1g TID
post-exposure 
passive 
immunization
VZIG (0.2-
1ml/kg IV) or 
IVIG (300-500 
mg/kg IV 
antiviral agents 
are until 21 
days post-
exposure 
 
passive 
immunization 
within 96 
hours of 
exposure 
Monitor if 
seropositive 
herpes zoster 
treatment with 
antivirals 
 
HHV-4 
(EBV) 
HSCT 
Baseline 
serologies 
GCV 
foscarnet 
cidofovir 
No evidence 
for the use of 
prophylactic 
therapy 
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Virus 
Disease 
---------------------
Population 
Surveillance
-----------------
(Monitoring)
Recommended 
antiviral agent
Preventative 
measure 
Timing and 
Duration 
HHV-5 
(CMV) 
Reactivation 
CMV viraemia 
CMV syndrome
Organ Disease 
(CNS, 
pneumonitis, GI)
Baseline 
serologies, 
weekly CMV 
PCR or pp65 
antigenemia
GCV 
foscarnet 
cidofovir 
VGCV 
Pre-emptive IV 
GCV 5mg/kg 
BID 
oral VGCV 
900mg BID 
 
HSCT 
weekly CMV 
PCR or pp65 
antigenemia
chemotherapy 
to 2-6 months, 
post therapy 
treatment for at 
least 1 week  or 
until CMV 
PCR is 
negative and 
patient 
asymptomatic 
Alemtuzumab 
therapy 
HHV-6  
Baseline 
serologies ? 
foscarnet 
GCV 
No evidence 
for the use of 
prophylactic 
therapy 
 
HHV-7  
Baseline 
serologies ? 
GCV 
foscarnet 
cidofovir 
No evidence 
for the use of 
prophylactic 
therapy 
 
HHV-8 
(KSHV) 
 
Baseline 
serologies ? 
GCV 
foscarnet 
cidofovir 
nelfinavir 
No evidence 
for the use of 
prophylactic 
therapy 
 
Abbreviations: ACV-acyclovir, GCV-ganciclovir, VACV-valacyclovir, VGCV-valganciclovir, HSCT-
hematopoietic stem cell transplantation, GVHD-graft-versus-host disease, IV-intavenous, BID-two times 
per day, TID-three times per day, QID-four times per day, VZIG-Varicella-zoster immunoglobulin, 
IVIG-intravenous immunoglobulin, FAM-Famciclovir, CNS-central nervous system, GI-gastrointestinal 
Table 1. Recommendations for Surveillance and Prophylaxis in Patients with Hematologic 
Diseases 
Viral infections remain a common complication in patients with hematologic diseases, 
especially in those receiving intensive chemotherapy. Fortunately, there are effective 
prophylactic and preventative mesures available to help control these infections. 
Human herpesviruses have been implicated in the pathogenesis of several diseases. An 
increasing number of malignancies are being associated with EBV (e.g. LPD, non-Hodgkin’s 
lymphoma, Hodgkin’s diseases, Burkitts’s lymphoma, NK-cell leukemia). HHV-8 has been 
suggested as a possible etiologic agent of several diseases. These include multiple myeloma, 
Waldenstörm’s macroglobulinaemia, and monoclonal gammopathy with unknown 
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significance. Multiple myeloma is a genetically and clinically heterogeneous disease. 
Recently, (at least) 5 prognostically and biologically different subgroups have been 
described based on karyotype and type of cyclin expression (Gertz & Greipp 2004). HHV-8 
infection may play a role in the disease process of only one or more subgroups of myeloma 
patients while not in others. In the history of HHV-8 research, it has been exceedingly 
difficult to obtain lymphoid cell lines (e.g. effusion lymphoma) devoid of EBV genome 
(Renne et al. 1996).  
This brings up the point of possible interaction between these two lymphotropic 
herpesviruses, at least in diseases of the lymphoid system. A similar interaction of HHV-6 
and 8 has been described in vitro. EBV-seronegative patients may be prone to HHV-8 
reactivation, the possible interaction of EBV early proteins with the activation of latently 
harbored HHV-8 genomes. This might occur also in such cases when the two viruses are not 
replicating in the same cell, but viral membrane proteins i.e. ZEBRA or interleukin-like 
molecules shed (IL10) by the EBV producing B-cells might interact with B cells or bone 
marrow cells carrying latent HHV-8 mini-chromosomes.  
It may be possible that the continuously replicating myeloma cells release both EBV and 
HHV-8, since latent virus infected cells are usually blocked in the G0-G1 phases of the cell 
cycle. When myeloma cells enter the S-phase, the availability of DNA replication machinery 
may activate the DNA viruses persisting in a small proportion of cells. The absence of CMV 
reactivation can be understood, since the sites of latency are the CD34+ progenitor cells of 
monocytes. The main site of replication is the B lymphocytes and many other cells in the 
human body. In conclusion, the data also indicate that in addition to HHV-8, the transitional 
reactivation of EBV may also play a role in the pathogenesis of MM (Csire et al. 2007b). 
Prospective studies are needed to clarify the spectrum of viral infections and risk factors for 
disease better, and to define effective prevention and treatment strategies. Fortunately, 
clinicians and virologists are increasingly aware of the most appropriate therapeutic options 
based on improved monitoring and characteriziation of the antiviral therapy. 
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